Exchange: EURONEXT Industry: Biotechnology
0.00% €0.229
America/New_York / 31 des 1970 @ 19:00
RATING 2022-02-17 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Strong Buy | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/19 | 2/19 | 4/19 | 2/20 | 4/20 | 2/21 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
Asset | n/a | n/a | n/a | n/a | n/a | n/a |
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -32.71 | sector: PE 17.68 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -32.71 | industry: PE -7.48 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
€ 0 - 0 ( +/- 0.00%) |
ATR Model: 14 days |
ASIT Biotech S.A., a biopharmaceutical company, focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies in Belgium and internationally. Its lead product is gp-ASIT+, which is in the Phase III trial for the treatment of grass pollen rhinitis. The company is also developing hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy. ASIT Biotech S.A. was incorporated in 1997 and is based in Liege, Belgium.